Ключевые слова
Как цитировать
Аннотация
Несмотря на успехи химиотерапии первой линии классической лимфомы Ходжкина, у части пациентов развивается рецидив или рефрактерное течение заболевания. стандартом лечения рецидива в течение последних лет по-прежнему является терапия «спасения» с последующей высокодозной химиотерапией и аутологичной трансплантацией гемопоэтических стволовых клеток крови. Брентуксимаб ведотин, совершивший настоящую революцию в лечении пациентов с лимфомой Ходжкина, показал свою высокую эффективность не только в лечении рецидива, но и в качестве поддерживающей опции после аутологичной трансплантации в группе пациентов высокого риска. В эру новых агентов для пациентов с рецидивом после аутологичной трансплантации костного мозга существует несколько терапевтических подходов в виде моно- и полихимиотерапии, конъюгата моноклонального антитела брентуксимаб, иммунотерапии «check-point» ингибиторами ниволумаб и пембролизумаб. Аллогенная трансплантация может быть рассмотрена у молодых пациентов с химиочувствительной опухолью при наличии донора костного мозга. Выбор терапевтического подхода должен всегда осуществляться с учетом возраста, сопутствующих заболеваний, предшествующего лечения, предпочтений пациента и лекарственных возможностей.Библиографические ссылки
Siegel R.L. Miller K.D. Jemal A. Cancer Statistics 2016 // CA Cancer J. Clin. - 2016. - Vol. 66. - P. 7-30.
Engert A., Diehl V., Franklin J. et al. Escalated-dose BEA-COPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 stud // Clin Oncol. - 2009. - Vol. 27(27). - P. 4548.
Engert A., Plutschow A., Eich H.T. et al. Reduced treatment intensity in patients with early stage Hodgkin's lymphoma // N. Engl. J. Med. - 2010. - Vol. 363(7). - P. 640-652.
von Tresckow B., Plutschow A., Fuchs M. et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial // J. Clin. Oncol. - 2012. - Vol. 30(9). - P. 907913.
Connors J.M., Jurczak W., Straus D.J., Alekseev S. et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma // N. Engl. J. Med. - 2017.
Engert A., Plütschow A., Eich H.T. et al. Reduced treatment intensity in patients with early-stage Hodgkin>s lymphoma. SON // Engl. J. Med. - 2010. - Vol. 363(7). -P. 640.
von Tresckow B., Engert A. The role of autologous transplantation in Hodgkin lymphoma // Curr. Hematol. Malig. Rep. - 2011. - Vol. 6(3). - P. 172-179.
Morschhauser F., Brice P., Ferme C. et al. Risk-adapted salvage treatment with single or tandem autologous stemcell transplantation for first relapse/refractory Hodgkin>s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group // J. Clin. Oncol. - 2008. - Vol. 26(36). - P. 5980-5987.
Younes A., Gopal A.K., Smith S.E. et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin>s Lymphoma // J. Clin. Oncol. - 2012. - Vol. 30(18). - P. 2183-2189.
Tim Illidge, Reda Bouabdallah,Robert Chen et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma // Leukemia & Lymphoma. - 2015. - Vol. 56. - Issue 3.
Garciaz S., Coso D., Peyrade F. et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma // Hematol. Oncol. - 2014. - Vol. 32(4). - P. 187-191.
Ansell S.M., Lesokhin A.M., Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin>s lymphoma // N. Engl. J. Med. - 2015. - Vol. 372(4). -P. 311-319.
Linch D.C., Winfield D., Goldstone A.H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkins disease: results of a BNLI randomised trial // Lancet. - 1993. - Vol. 341(8852). - P. 1051-1054.
Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin>s disease: a randomised trial // Lancet. - 2002. - Vol. 359(9323). - P. 2065-2071.
Rancea M., Monsef I., von Tresckow B. et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma // The Cochrane database of systematic reviews. - 2013. - Vol. 6. - CD009411.
Ansell S.M. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management // Am. J. Hematol. - 2016. - Vol. 91(4). - P. 434-442.
sureda A., Constans M., Iriondo A. et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse // Ann. Oncol. - 2005. - Vol. 16(4). - P. 625-633.
von Tresckow B., Moskowitz C. Relapsed and Refractory Hodgkin Lymphoma. In: Engert A, Younes A, editors. Hodgkin Lymphoma // Springer International Publishing. - 2015. - P 321-330.
Moskowitz C.H., Glassman J.R., Wuest D. et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma // Clinical cancer research: an official journal of the American Association for Cancer Research. - 1998. - Vol. 4(2). - P. 311-316.
Moskowitz C.H., Nimer S.D., Zelenetz A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model // Blood. - 2001. - Vol. 97(3). - P 616-623.
Josting A., Rudolph C., Reiser M. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease // Ann. Oncol. - 2002. - Vol. 13(10). - P. 1628-1635.
Aparicio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin's disease // Ann. Oncol. - 1999. - Vol. 10(5). - P 593-595.
Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma // Blood. - 2011. - Vol. 117. - P 4208-4217.
Josting A., Franklin J., May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group // J. Clin. Oncol. - 2002. - Vol. 20(1). - P 221-230.
Aparicio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkins disease // Ann. Oncol. - 1999. - Vol. 10(5). - P 593-595.
Mehrzad V., Ashrafi F., Farrashi A.R. et al. Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma // Adv. Biomed. Res. - 2017. - Vol. 6. - P 30.
Abali H., Urün Y, Oksüzoglu B. et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma // Cancer Invest. - 2008. - Vol. 26(4). - P. 401-406.
Sasse S., Alram M., Muller H. et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group // Leuk Lymphoma. - 2015. - P. 1-7.
Bartlett N.L., Niedzwiecki D., Johnson J.L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin>s lymphoma: CALGB 59804 // Ann. Oncol. - 2007. - Vol. 18(6). - P. 1071-1079.
Santoro A., Magagnoli M., Spina M. et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin>s lymphoma //Haematologica. - 2007. - Vol. 92(1). - P. 35-41.
Mart n A., Fernandez-Jimenez M.C., Caballero M.D. et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease // Br. J. Haematol. - 2001. - Vol. 113(1). - P. 161-171.
Kuruvilla J., Nagy T., Pintilie M. et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma // Cancer. - 2006. - Vol. 106. - P. 353-360.
Moskowitz C.H., Kewalramani T., Nimer S.D. et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease // Br. J. Haematol. - 2004. - Vol. 124. - P 645-652.
Smardova L., Engert A., Haverkamp et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin>s disease // Leuk Lymphoma. - 2005. - Vol. 46. - P 1017-1022.
Akhtar S., Tbakhi A., Humaidan H. et al. ESHAP + fixed dose G-CSF as auto logous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin>s lymphoma: a single institution result of 127 patients // Bone Marrow Transplant. - 2006. - Vol. 37. - P 277-282.
Sutherland M.S.K., Sanderson R.J., Gordon K.A. et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates // Journal of Biological Chemistry. - 2006. - Vol. 281(15). - P 10540-10547.
Chen R., Palmer J.M., Martin P. et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. // Biol Blood Marrow Transplant 2015 Dec;21(12):2136-40.
Moskowitz AJ, Schoder H, Yahalom J, и др. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin>s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. // Lancet Oncol 2015 Mar;16(3):284-92.
LaCasce AS, Bociek G, Sawas A, и др. Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. //Blood 2015 126(23):3982.
Garcia-Sanz R, Sureda A, Alonso-Alvarez S, и др. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). //Blood 2015 126(23):582.
Josting A, Rueffer U, Franklin J, и др. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. //Blood. 2000;96(4):1280-1286.
Crump M, Smith AM, Brandwein J, и др. Highdose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. //J Clin Oncol. 1993;11(4):704- 711.
Ferme' C, Bastion Y Lepage E, и др. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. // Ann Oncol. 1995;6(6):543-549.
Lohri A, Barnett M, Fairey RN, и др. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. //Blood. 1991;77(10):2292-2298.
Bierman PJ, Lynch JC, Bociek RG, и др. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. //Ann Oncol. 2002;13(9):1370- 1377.
Reece DE, Barnett MJ, Shepherd JD и др. Highdose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV / P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. //Blood. 1995;86(2):451-456.
Pfreundschuh MG, Rueffer U, Lathan B, и др. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. //J Clin Oncol. 1994;12(3):580-586
Martin A, Fernandez-Jimenez MC, Caballero MD и др. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. //Br J Haematol. 2001;113(1):161-171.
Josting A, Rudolph C, Mapara M, и др. Cologne highdose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). //Ann Oncol. 2005;16(1):116-123.
Stewart DA, Guo D, Gluck S, др. Double highdose therapy for Hodgkin's disease with doseintensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. // Bone Marrow Transplant. 2000;26 (4):383-388.
Stuart MJ, Chao NS, Horning SJ, и др. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. //Biol Blood Marrow Transplant. 2001;7(10):552-560
Evens A, Altman J, Mittal B, и др. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. // Ann Oncol. 2007;18(4):679-688
Ferme' C, Mounier N, Divine M, и др. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. //J Clin Oncol. 2002;20(2):467- 475
Bierman PJ, Bagin RG, Jagannath S, и др. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: longterm follow-up in 128 patients. Ann Oncol. 1993; 4(9):767-773.
C. H. Moskowitz, A. Nademanee, T. Masszi и др., "Bren-tuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, doubleblind, placebo-controlled, phase 3 trial, // The Lancet, vol. 385, no. 9980, pp. 1853-1862, 2015.
von Tresckow B, Muller H, Eichenauer DA, et al. Outcome and risk factors of Hodgkin Lymphoma patients who re lapse or progress after autologous stem cell transplant. Leuk Lymphoma 2013 Oct 21.
Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013 May 26.
Lapo Alinari и Kristie A. Blum. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell trans-plant//Blood 2016 127:287-295
Moskowitz AJ, Hamlin PA Jr, Perales MA, и др. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.// J Clin Oncol. 2013; 31(4):456-460.
Clozel T, Deau B, Benet C, и др. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation. //Br J Haematol. 2013;162(6):846-848.
Fedele R., Martino M., Recchia A.G и др. Clinical options in relapsed or refractory Hodgkin lymphoma: an updated review. // J Immunol Res. 2015;2015:968212.
Chen R, Gopal AK, Smith S и др. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. // Blood 2016; 128: 1562-1566.
Moskowitz CH, Ribrag V, Michot J-M, и др. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1B study (Keynote-013). // Blood. 2014; 124(21).
Fehniger TA, Larson S, Trinkaus K, и др. A phase 2 multi-center study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. // Blood. 2011;118(19):5119-5125.
Younes A, Sureda A, Ben-Yehuda D, и др. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. // J Clin Oncol. 2012;30(18):2197-2203.
Younes A, Santoro A, Shipp M и др. Nivolumab for classical Hodgkin s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial //Lancet Oncol. 2016 Sep;17(9):1283-94.
Armand P, Shipp MA, Ribrag V и др. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.//J Clin Oncol. 2016 Nov 1;34(31):3733-3739.
Chen R, Zinzani PL, Fanale MA и др. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.//J Clin Oncol. 2017 Jul 1;35(19):2125-2132.
Sureda A, Robinson S, Canals C, и др. Reducedinten-sity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. //J Clin Oncol. 2008;26(3):455-462.
Burroughs LM, O'Donnell PV, Sandmaier BM, и др. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. // Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
Raiola A, Dominietto A, Varaldo R, и др. Unmanipulated haploidentical BMT following non-myeloablative conditioning and posttransplantation CY for advanced Hodgkin's lymphoma. // Bone Marrow Transplant. 2014; 49(2):190-194.
Moskowitz AJ, Yahalom J, Kewalramani T, и др. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.//Blood 2010 Dec 2;116(23):4934-7.
Moskowitz CH, Matasar MJ, Zelenetz ADm др. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. //Blood 2012 Feb 16;119(7):1665-70.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2018